On October 2, 2023 AskAt reported a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) dated September 6, 2023 for an EP4 receptor antagonist use patent for the treatment of cancer, particularly for the use of grapiprant in the treatment of cancer (Press release, AskAt, OCT 2, 2023, View Source [SID1234635558]). The Notice was issued in connection with Application Number 17/201,102. AskAt’s EP4 receptor antagonist cancer use patent (Filing Date: April 22, 2010) has already been granted in Japan, the United States, Europe, Canada, China, Korea, Mexico, Brazil, Russia, and Hong Kong. This will reinforce the protection of a patent in the United States.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On October 2, 2023 ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, reported the hosting of an investor call and webcast on Tuesday, October 3rd at 8:00 AM EDT to share interim Phase 2 ASPEN-06 clinical trial results of evorpacept for the treatment of advanced HER2-positive gastric cancer (Press release, ALX Oncology, OCT 2, 2023, View Source [SID1234635557]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the live conference call, please dial (800) 715-9871 (U.S./Canada) or +44.800.260.6466 (internationally), Conference ID 7797378. To access the live and archived webcast of the conference call, please visit the News & Events section (see "Events") of the Company’s website at www.alxoncology.com where a slide presentation will be referenced during the event.